AstraZeneca plc (LON:AZN) has received an average recommendation of “Hold” from the nineteen ratings firms that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is GBX 6,693.75 ($87.47).
Several analysts have issued reports on AZN shares. Jefferies Financial Group cut their price target on AstraZeneca from GBX 6,400 ($83.63) to GBX 6,350 ($82.97) and set a “hold” rating for the company in a report on Friday, May 24th. Kepler Capital Markets set a GBX 6,470 ($84.54) target price on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Monday, May 13th. UBS Group reiterated a “sell” rating and set a GBX 5,700 ($74.48) target price (up previously from GBX 5,400 ($70.56)) on shares of AstraZeneca in a research note on Wednesday. Bryan, Garnier & Co restated a “neutral” rating on shares of AstraZeneca in a research note on Wednesday, July 3rd. Finally, Citigroup restated a “buy” rating and issued a GBX 7,000 ($91.47) price objective on shares of AstraZeneca in a research note on Monday, May 13th.
AstraZeneca stock traded down GBX 39 ($0.51) during mid-day trading on Friday, reaching GBX 7,230 ($94.47). 1,454,027 shares of the stock traded hands, compared to its average volume of 2,310,000. The firm has a market capitalization of $94.85 billion and a PE ratio of 42.23. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. AstraZeneca has a 12-month low of GBX 5,312 ($69.41) and a 12-month high of GBX 7,349.30 ($96.03). The firm’s 50-day simple moving average is GBX 6,738.50.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: What is meant by holder of record?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.